UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Risk factors for Klebsiella pneumoniae carbapenemase (KPC) gene acquisition and clinical outcomes across multiple bacterial species

Mathers, A; Vesegana, K; German Mesner, I; Ainsworth, J; Pannone, A; Crook, D; Sifri, C; ... Eyre, D; + view all (2020) Risk factors for Klebsiella pneumoniae carbapenemase (KPC) gene acquisition and clinical outcomes across multiple bacterial species. Journal of Hospital Infection , 104 (4) pp. 456-468. 10.1016/j.jhin.2020.01.005. Green open access

[thumbnail of Walker_1-s2.0-S0195670120300074-main.pdf]
Preview
Text
Walker_1-s2.0-S0195670120300074-main.pdf - Published Version

Download (410kB) | Preview

Abstract

Introduction: Risk-factors for carbapenemase-producing Enterobacteriales (CPE) acquisition/infection and associated clinical outcomes have been evaluated in the context of clonal, species-specific outbreaks; equivalent analyses for complex, multi-species outbreaks, which are increasingly common, are lacking. Methods: We performed a case-control study of Klebsiella pneumoniae carbapenemase (KPC)-producing organism (KPCO) acquisition using electronic health records from inpatients in a US academic medical center and long-term acute care hospital (LTACH), Dec 2010-Jan 2017, with ongoing multi-species KPCO transmission despite a robust CPE screening program. Cases had a first KPCO-positive culture >48 hours after admission, and included colonisations and infections (defined by clinical records). Controls had ≥2 negative peri-rectal screens and no positive cultures. Risk-factors for KPCO acquisition, first infection following acquisition, and 14-day mortality following each infection episode were identified using multivariable logistic regression. Results In 303 cases (89 with ≥1 infection) and 5929 controls, risk-factors for KPCO acquisition included: longer inpatient stay, transfusion, complex thoracic pathology, mechanical ventilation, dialysis, and exposure to carbapenems and β-lactam/β-lactamase inhibitors. Exposure to other KPCO-colonised patients was only a risk factor for acquisition in a single unit, suggesting that direct patient-to-patient transmission did not play a major role. There were 15 species of KPCO; 61 (20%) cases were colonised/infected with >1 species. 14-day mortality following non-urinary KPCO infection was 20% (20/97 episodes) and was associated with failure to achieve source control. Conclusions: Healthcare exposures, antimicrobials and invasive procedures increased risk of KPCO colonisation/infection suggesting potential targets for infection control interventions in multi-species outbreaks. Evidence for patient-to-patient transmission was limited.

Type: Article
Title: Risk factors for Klebsiella pneumoniae carbapenemase (KPC) gene acquisition and clinical outcomes across multiple bacterial species
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.jhin.2020.01.005
Publisher version: https://doi.org/10.1016/j.jhin.2020.01.005
Language: English
Additional information: This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Carbapenemase producing Enterobacteriales (CPE), Carbapenemase producing organisms (CPO), Klebsiella pneumoniae carbapenemase (KPC), multispecies clinical risk, carbapenem resistant Enterobacteriales (CRE)
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10088866
Downloads since deposit
8,360Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item